| (19) |
 |
|
(11) |
EP 2 500 037 A3 |
| (12) |
EUROPEAN PATENT APPLICATION |
| (88) |
Date of publication A3: |
|
24.10.2012 Bulletin 2012/43 |
| (43) |
Date of publication A2: |
|
19.09.2012 Bulletin 2012/38 |
| (22) |
Date of filing: 16.05.2006 |
|
| (51) |
International Patent Classification (IPC):
|
|
| (84) |
Designated Contracting States: |
|
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE
SI SK TR |
|
Designated Extension States: |
|
BA HR MK YU |
| (30) |
Priority: |
16.05.2005 US 681645 P
|
| (62) |
Application number of the earlier application in accordance with Art. 76 EPC: |
|
06770998.0 / 1885397 |
| (71) |
Applicant: Abbott Biotechnology Ltd |
|
HM 11 Hamilton (BM) |
|
| (72) |
Inventors: |
|
- Hoffman, Rebecca, S.
Wilmette, IL 60091 (US)
- Weinberg, Mark
Wilmette, IL 60091 (US)
|
| (74) |
Representative: Modiano, Micaela Nadia |
|
Modiano & Partners (DE)
Thierschstrasse 11
80538 München
80538 München (DE) |
|
| |
|
| (54) |
Use of TNF alpha inhibitor for treatment of erosive polyarthritis |
(57) The invention describes methods of treating erosive polyarthritis comprising administering
a TNFα antibody, or antigen-binding portion thereof. The invention also describes
a method for testing the efficacy of a TNFα antibody, or antigen-binding portion thereof,
for the treatment of erosive polyarthritis